GenSight Biologics

Magali Taiel, M.D., Chief Medical Officer

April 21 | 12:00pm | Gaudi 3 Ballroom

Paris, France


In-Person Presentation

GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. GenSight Biologics’ lead product candidate, LUMEVOQ®, has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. GS030, an optogenetic therapy combining gene therapy with a light-modulating medical device, is in a Phase I/II trial for retinitis pigmentosa.

By using this website you agree to accept our Privacy Policy and Terms & Conditions